Wearable and implantable devices for drug delivery: Applications and challenges.

Poor adherence to drug dosing schedule is responsible for ∼50% of hospitalization cases. Most patients fail to adhere to a strict dosing schedule due to invasive drug administration, off-target toxicities, or medical conditions like dementia. The emerging concept of wearable devices (WDs), implantable devices (IDs) and combined wearable and implantable devices (WIDs) for drug delivery has created new opportunities for treating patients with chronic diseases needing repeated and long-term medical attention like diabetes, ocular disorders, cancer, wound healing, cardiovascular diseases, and contraception. WDs, worn on the body surface have created appealing non-invasive, self-administrable drug delivery platforms which receive huge patient compliance. Microneedle-skin patches, wound healing patches, drug-eluting contact lenses, mouth guards, intra-vaginal rings, pharmaceutical jewelry, and drug-loaded self-care textiles are popular WDs explored in drug delivery. In contrast, IDs are surgically placed inside body tissue allowing higher payload and enhanced localized effect for an extended duration. Hormone micropumps, hydrogel/nanofibrous depot, coronary stents, intravitreal devices, and intrauterine devices are some representative examples of IDs. In this review, we have described the past 10 years of research progress on drug-delivering WDs and IDs in the context of treating diseases that demand repeated and long-term medication, especially those affecting soft tissues. We highlighted several technical challenges that need to be addressed before considering the translation of such technologies to clinics.

Mapping Fusogenicity of Ciprofloxacin-Loaded Liposomes with Bacterial Cells.

The process of liposome fusion with cellular membrane plays key role in delivering encapsulated drug molecule into the cell. This process becomes very important for molecules having low permeability as they fail to reach the site of action located inside the cell. Ciprofloxacin (CIP), a broad-spectrum BCS class IV antibiotic, has poor permeability. In the present work, CIP-loaded liposomes were prepared using solvent evaporation method and optimized by 32 factorial design approach. The optimized batch of CIP-loaded liposomes was characterized for size, entrapment efficiency, zeta potential, FTIR, and microbial susceptibility study on Staphylococcus aureus (gram-positive bacteria) and Escherichia coli (gram-negative bacteria). Confocal microscopy was used to study the fusogenicity process of CIP-loaded liposomes with bacterial cells. Additionally, the kinetics of fusogenicity process was studied using SAXS for the first time. Surprisingly, the rate of fusion of CIP-loaded liposomes with cell wall of S. aureus was twice when compared to the cell wall of E. coli. It is believed that the current work can act as a roadmap in selection of proper excipients while developing formulations which would expedite the fusogenicity and may execute pharmacological activity of poorly penetrable drug molecules at lower dose.